Copy to clipboard 
Globus Medical reported 2Q25 orthopedic sales of $745.3 million, up 18.4% compared to the second quarter of 2024. Newly-acquired Nevro contributed $94.5 million in the quarter, resulting in legacy Globus sales growth of 3.3%. For the first half of 2025, the company generated $1.34 billion in orthopedic sales, up 8.7% on a reported basis and 1% on an organic basis.
Globus faced operational challenges in the first quarter related to product supply. Delivery of U.S. spine sets largely returned to normal in the second quarter, while international supply improved gradually through the quarter.
Likewise, Globus’ notably soft first quarter enabling technology sales improved sequentially in the second quarter, but still declined on a year-over-year basis. The company said sales cycles for technology remain elongated.
“I still see that elongation pipeline,” said Globus Medical CEO Keith Pfeil. “We’re still selling outright the majority of our robots. As I look at our pipeline, I don’t see us losing deals to competition. I view our #1 competitor as Medtronic. We go head-to-head with them, but we still think the superiority of our technology puts us ahead of the class.”
Globus reaffirmed its 2025 guidance of revenue in the range between $2.8 billion and $2.9 billion.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $539.8 | $527.3 | $12.4 | 2.4% |
| Trauma | $36.4 | $27.1 | $9.3 | 34.5% |
| Orthobiologics | $39.4 | $38.5 | $0.9 | 2.3% |
| Enabling Technology | $35.2 | $36.8 | ($1.6) | (4.4%) |
| Other | $94.6 | |||
| Total | $745.3 | $629.7 | $115.7 | 18.4% |
| Segment | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $1,057.5 | $1,039.0 | $18.5 | 1.8% |
| Trauma | $60.0 | $52.7 | $7.3 | 13.8% |
| Orthobiologics | $74.0 | $75.9 | ($1.9) | (2.5%) |
| Enabling Technology | $57.3 | $68.7 | ($11.4) | (16.6%) |
| Other | $94.6 | |||
| Total | $1,343.5 | $1,236.4 | $107.1 | 8.7% |
Orthopedic Sales by Geography
| Region | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $600.8 | $499.5 | $101.3 | 20.3% |
| OUS | $144.6 | $130.2 | $14.3 | 11% |
| Total | $745.3 | $629.7 | $115.7 | 18.4% |
| Region | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,084.6 | $982.4 | $102.3 | 10.4% |
| OUS | $258.8 | $254.0 | $4.9 | 1.9% |
| Total | $1,343.5 | $1,236.4 | $107.1 | 8.7% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $745.3 | |
| Cost of Sales | $284.8 | 38.2% |
| R & D | $40.0 | 5.4% |
| Selling and Admin | $303.6 | 40.7% |
| Other | $62.1 | 8.3% |
| Net Earnings | $202.8 | 27.2% |
Globus Medical reported 2Q25 orthopedic sales of $745.3 million, up 18.4% compared to the second quarter of 2024. Newly-acquired Nevro contributed $94.5 million in the quarter, resulting in legacy Globus sales growth of 3.3%. For the first half of 2025, the company generated $1.34 billion in orthopedic sales, up 8.7% on a reported basis and...
Globus Medical reported 2Q25 orthopedic sales of $745.3 million, up 18.4% compared to the second quarter of 2024. Newly-acquired Nevro contributed $94.5 million in the quarter, resulting in legacy Globus sales growth of 3.3%. For the first half of 2025, the company generated $1.34 billion in orthopedic sales, up 8.7% on a reported basis and 1% on an organic basis.
Globus faced operational challenges in the first quarter related to product supply. Delivery of U.S. spine sets largely returned to normal in the second quarter, while international supply improved gradually through the quarter.
Likewise, Globus’ notably soft first quarter enabling technology sales improved sequentially in the second quarter, but still declined on a year-over-year basis. The company said sales cycles for technology remain elongated.
“I still see that elongation pipeline,” said Globus Medical CEO Keith Pfeil. “We’re still selling outright the majority of our robots. As I look at our pipeline, I don’t see us losing deals to competition. I view our #1 competitor as Medtronic. We go head-to-head with them, but we still think the superiority of our technology puts us ahead of the class.”
Globus reaffirmed its 2025 guidance of revenue in the range between $2.8 billion and $2.9 billion.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $539.8 | $527.3 | $12.4 | 2.4% |
| Trauma | $36.4 | $27.1 | $9.3 | 34.5% |
| Orthobiologics | $39.4 | $38.5 | $0.9 | 2.3% |
| Enabling Technology | $35.2 | $36.8 | ($1.6) | (4.4%) |
| Other | $94.6 | |||
| Total | $745.3 | $629.7 | $115.7 | 18.4% |
| Segment | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $1,057.5 | $1,039.0 | $18.5 | 1.8% |
| Trauma | $60.0 | $52.7 | $7.3 | 13.8% |
| Orthobiologics | $74.0 | $75.9 | ($1.9) | (2.5%) |
| Enabling Technology | $57.3 | $68.7 | ($11.4) | (16.6%) |
| Other | $94.6 | |||
| Total | $1,343.5 | $1,236.4 | $107.1 | 8.7% |
Orthopedic Sales by Geography
| Region | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $600.8 | $499.5 | $101.3 | 20.3% |
| OUS | $144.6 | $130.2 | $14.3 | 11% |
| Total | $745.3 | $629.7 | $115.7 | 18.4% |
| Region | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,084.6 | $982.4 | $102.3 | 10.4% |
| OUS | $258.8 | $254.0 | $4.9 | 1.9% |
| Total | $1,343.5 | $1,236.4 | $107.1 | 8.7% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $745.3 | |
| Cost of Sales | $284.8 | 38.2% |
| R & D | $40.0 | 5.4% |
| Selling and Admin | $303.6 | 40.7% |
| Other | $62.1 | 8.3% |
| Net Earnings | $202.8 | 27.2% |
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
